HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor

Gynecologic Oncology

Volumn 131, Issue 3, 2013, Pages 753-758

  English, Diana P ^a   Roque, Dana M ^a   Carrara, Luisa ^b   Lopez, Salvatore ^c   Bellone, Stefania ^a   Cocco, Emiliano ^a   Bortolomai, Ileana ^a   Schwartz, Peter E ^a   Rutherford, Thomas ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Endometrial neoplasms; HER2 neu; mTOR inhibitor AZD8055; Uterine serous tumors

Indexed keywords

AZD 8055; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN S6;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CONTENT; DRUG RESPONSE; ENDOMETRIUM CARCINOMA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GROWTH CURVE; GROWTH INHIBITION; GROWTH RATE; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ENDOMETRIAL NEOPLASMS; HER2/NEU; MTOR INHIBITOR AZD8055; UTERINE SEROUS TUMORS;

ANTINEOPLASTIC AGENTS; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE AMPLIFICATION; HUMANS; MORPHOLINES; MULTIPROTEIN COMPLEXES; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; TOR SERINE-THREONINE KINASES; UTERINE NEOPLASMS;

EID: 84888287601     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.08.033     Document Type: Article

References (31)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. J.V. Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 1983 10 17
3. M. Hendrickson, J. Ross, P. Eifel, A. Martinez, and R. Kempson Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma Am J Surg Pathol 6 1982 93 108
4. P.E. Schwartz The management of serous papillary uterine cancer Curr Opin Oncol 18 2006 494 499
5. C.A. Hamilton, M.K. Cheung, K. Osann, L. Chen, N.N. Teng, and T.A. Longacre Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers Br J Cancer 94 2006 642 646
6. D.P. English, D.M. Roque, and A.D. Santin HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies Mol Diagn Ther 17 2013 85 99
7. J.E. Dancey Therapeutic targets: MTOR and related pathways Cancer Biol Ther 5 2006 1065 1073
8. Q.B. She, S. Chandarlapaty, Q. Ye, J. Lobo, K.M. Haskell, and K.R. Leander Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling PLoS One 3 2008 e3065
9. S.M. Brachmann, I. Hofmann, C. Schnell, C. Fritsch, S. Wee, and H. Lane Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells Proc Natl Acad Sci USA 106 2009 22299 22304
10. D.R. Boulbes, T. Shaiken, and D. Sarbassov dos Endoplasmic reticulum is a main localization site of mTORC2 Biochem Biophys Res Commun 413 2011 46 52
11. X. Liu, and X.F. Zheng Endoplasmic reticulum and Golgi localization sequences for mammalian target of rapamycin Mol Biol Cell 18 2007 1073 1082
12. M. Rosner, and M. Hengstschlager Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1 Hum Mol Genet 17 2008 2934 2948
13. Q. Shen, M.L. Stanton, W. Feng, M.E. Rodriguez, L. Ramondetta, and L. Chen Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma Int J Clin Exp Pathol 4 2010 13 21
14. C. Y-J Targeted mTOR in human gynecologic cancers J Cancer Mol 3 2007 101 106
15. G. Marshall, Z. Howard, J. Dry, S. Fenton, D. Heathcote, and N. Gray Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055 Biochem Soc Trans 39 2011 456 459
16. C.M. Chresta, B.R. Davies, I. Hickson, T. Harding, S. Cosulich, and S.E. Critchlow AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity Cancer Res 70 2010 288 298
17. P. Sini, D. James, C. Chresta, and S. Guichard Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells Autophagy 6 2010 553 554
18. S.N. Cross, E. Cocco, S. Bellone, V.K. Anagnostou, S.L. Brower, and C.E. Richter Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro Am J Obstet Gynecol 203 2010 [162 e1-8]
19. D.M. Roque, S. Bellone, D.P. English, N. Buza, E. Cocco, and S. Gasparrini Tubulin-beta-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones Cancer 2013
20. N. Kotecha, N.J. Flores, J.M. Irish, E.F. Simonds, D.S. Sakai, and S. Archambeault Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates Cancer Cell 14 2008 335 343
21. S. Zhao, M. Choi, J.D. Overton, S. Bellone, D.M. Roque, and E. Cocco Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma Proc Natl Acad Sci USA 110 2013 2916 2921
22. A.M. Oza, L. Md, J. Elit, W. Biagi, M. Chapman, D. Tsao, and C. Hedley Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer-NCICIND 160 J Clin Oncol 24 2006 121
23. N. Colombo, S. McMeekin, P. Schwartz, J. Kostka, C. Sessa, and P. Gehrig A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer J Clin Oncol 25 2007 5516
24. V.L. Bae-Jump, C. Zhou, J.F. Boggess, Y.E. Whang, L. Barroilhet, and P.A. Gehrig Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment Gynecol Oncol 119 2010 579 585
25. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, and R.R. Broaddus A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 116 2010 5415 5419
26. Q. Zeng, Z. Yang, Y.J. Gao, H. Yuan, K. Cui, and Y. Shi Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study Eur J Cancer 46 2010 1132 1143
27. A. Shafer, C. Zhou, P.A. Gehrig, J.F. Boggess, and V.L. Bae-Jump Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis Int J Cancer 126 2010 1144 1154
28. B.J. Slomovitz BM, T.A. Johnston, D. Mura, C. Levenback, J. Wolf, and K.R. Adler A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma J Clin Oncol 2011 [(Suppl): Abstr. 5012]
29. T. Bachelot, C. Bourgier, C. Cropet, I. Ray-Coquard, J.M. Ferrero, and G. Freyer Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study J Clin Oncol 30 2012 2718 2724
30. H. Liu, C. Scholz, C. Zang, J.H. Schefe, P. Habbel, and A.C. Regierer Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro Anticancer Res 32 2012 1627 1637
31. K. Shoji, K. Oda, T. Kashiyama, Y. Ikeda, S. Nakagawa, and K. Sone Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas PLoS One 7 2012 e37431